Optimizing urinary tract infection outcomes: nitrofurantoin versus fluoroquinolones

The rising global prevalence of urinary tract infections and escalating antimicrobial resistance present a critical clinical challenge. Therefore, it is of interest to evaluate the clinical cure rates while minimizing adverse drug reactions (ADRs) and resistance, researchers studied 40 adult patients (80% female) divided into Group I (Nitrofurantoin) and Group II (Fluoroquinolones). Nitrofurantoin achieved a higher clinical cure rate (95%) with 4.75 times greater odds of success than fluoroquinolones (80%). The adverse reaction rate was significantly lower for nitrofurantoin (10% versus 26.7%), though both groups reported similar side effects. Thus, data shows the nitrofurantoin also maintained a lower failure rate (5% versus 15%), supporting its prioritization as a first-line empirical therapy.